Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype

Breast

Volumn 23, Issue 4, 2014, Pages 400-406

  Martinez de Dueñas, Eduardo ^a   Ochoa Aranda, Enrique ^a   Blancas Lopez Barajas, Isabel ^b   Ferrer Magdalena, Teresa ^a   Bandrés Moya, Fernando ^c   Chicharro García, Luis Miguel ^d   Gómez Capilla, José A ^b,e   Zafra Ceres, Mercedes ^b   de Haro, Tomás ^b   Romero Llorens, Regina ^a   Ferrer Albiach, Carlos ^a   Ferriols Lisart, Rafael ^f   Chover Lara, Dolores ^a   López Rodríguez, Ángela ^a   Munárriz Ferrandis, Javier ^a   Olmos Antón, Santiago ^a  

^a HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

^d UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^e UNIVERSITY OF GRANADA   (Spain)

^f HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

Breast cancer; CYP2D6; Dose adjustment; Endoxifen; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; ENDOXIFEN; TAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENOTYPE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN METABOLISM; THROMBOEMBOLISM; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PHENOTYPE; TAMOXIFEN;

EID: 84902547513     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.02.008     Document Type: Article

References (32)

1. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. JNatl Cancer Inst 2005, 97(1):30-39.
2. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006, 80(1):61-74.
3. Johnson M.D., Zuo H., Lee K.H., Trebley J.P., Rae J.M., Weatherman R.V., et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004, 85(2):151-159.
4. Murdter T.E., Schroth W., Bacchus-Gerybadze L., Winter S., Heinkele G., Simon W., et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011, 89(5):708-717.
5. Lim H.S., Ju Lee H., Seok Lee K., Sook Lee E., Jang I.J., Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. JClin Oncol 2007, 25(25):3837-3845.
6. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3(2):229-243.
7. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. JClin Oncol 2005, 23(36):9312-9318.
8. Newman W.G., Hadfield K.D., Latif A., Roberts S.A., Shenton A., McHague C., et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008, 14(18):5913-5918.
9. Kiyotani K., Mushiroda T., Imamura C.K., Hosono N., Tsunoda T., Kubo M., et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. JClin Oncol 2010, 28(8):1287-1293.
10. Schroth W., Goetz M.P., Hamann U., Fasching P.A., Schmidt M., Winter S., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302(13):1429-1436.
11. Thompson A.M., Johnson A., Quinlan P., Hillman G., Fontecha M., Bray S.E., et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 2011, 125(1):279-287.
12. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. JNatl Cancer Inst 2003, 95(23):1758-1764.
13. Nowell S.A., Ahn J., Rae J.M., Scheys J.O., Trovato A., Sweeney C., et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005, 91(3):249-258.
14. Abraham J.E., Maranian M.J., Driver K.E., Platte R., Kalmyrzaev B., Baynes C., et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010, 12(4):R64.
15. Lash T.L., Cronin-Fenton D., Ahern T.P., Rosenberg C.L., Lunetta K.L., Silliman R.A., et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. JNatl Cancer Inst 2011, 103(6):489-500.
16. Rae J.M., Drury S., Hayes D.F., Stearns V., Thibert J.N., Haynes B.P., et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. JNatl Cancer Inst 2012, 104(6):452-460.
17. Regan M.M., Leyland-Jones B., Bouzyk M., Pagani O., Tang W., Kammler R., et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. JNatl Cancer Inst 2012, 104(6):441-451.
18. Goetz M.P., Suman V.J., Hoskin T.L., Gnant M., Filipits M., Safgren S.L., et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013, 19(2):500-507.
19. Brauch H., Schroth W., Goetz M.P., Murdter T.E., Winter S., Ingle J.N., et al. Tamoxifen use in postmenopausal breast Cancer: CYP2D6 matters. JClin Oncol 2013, 31(2):176-180.
20. Fleeman N., Martin Saborido C., Payne K., Boland A., Dickson R., Dundar Y., et al. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess 2011, 15(33):1-102.
21. Heller T., Kirchheiner J., Armstrong V.W., Luthe H., Tzvetkov M., Brockmoller J., et al. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit 2006, 28(5):673-677.
22. Rebsamen M.C., Desmeules J., Daali Y., Chiappe A., Diemand A., Rey C., et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 2009, 9(1):34-41.
23. Lammers L.A., Mathijssen R.H., van Gelder T., Bijl M.J., de Graan A.J., Seynaeve C., et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 2010, 103(6):765-771.
24. Walko C.M., McLeod H. Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment. Pharmacogenomics 2012, 13(6):691-697.
25. Brauch H.B., Schroth W., Ingle J.N., Goetz M.P. CYP2D6 and tamoxifen: awaiting the denouement. JClin Oncol 2011, 29(34):4589-4590. author reply 4590-1.
26. Stanton V. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. JNatl Cancer Inst 2012, 104(16):1265-1266. author reply 1266-8.
27. Hertz D.L., McLeod H.L., Irvin W.J. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 2012, 17. [p. XXX-XXX].
28. Madlensky L., Natarajan L., Tchu S., Pu M., Mortimer J., Flatt S.W., et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011, 89(5):718-725.
29. Irvin W.J., Walko C.M., Weck K.E., Ibrahim J.G., Chiu W.K., Dees E.C., et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. JClin Oncol 2011, 29(24):3232-3239.
30. Kiyotani K., Mushiroda T., Imamura C.K., Tanigawara Y., Hosono N., Kubo M., et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat 2012, 131(1):137-145.
31. Barginear M.F., Jaremko M., Peter I., Yu C., Kasai Y., Kemeny M., et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 2011, 90(4):605-611.
32. Ziller V., Kalder M., Albert U.S., Holzhauer W., Ziller M., Wagner U., et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009, 20(3):431-436.